October 4, 2022

Fior Markets News Blog

Complete News World

The UK becomes the first country to approve Moderna’s dual Covid-19 vaccine

The UK becomes the first country to approve Moderna's dual Covid-19 vaccine

Britain has become the first country in the world to adopt Moderna’s bivalent Covid-19 vaccine, which targets the original strain of the virus and the newer Omicron variant.

Long Optical Press | global photo collection | Getty Images

Britain on Monday became the first country in the world to approve a dual vaccine for Covid-19, which treats both the original virus and the newer omicron variant.

updated Moderna The vaccine – known as bivalent because it targets two different species – is expected to be available to adults as a booster from autumn after receiving the green light from the UK’s Medicines and Healthcare products Regulatory Agency on Monday.

It has also been endorsed by the UK government’s independent scientific advisory body, the Commission on Human Medicines.

The MHRA said that while the current vaccines – which were designed to combat the original strain of Covid – continue to provide good protection, the booster version will provide better defense as the virus evolves.

“The first generation of Covid-19 vaccines used in the UK continues to provide important protection against disease and save lives. What this bivalent vaccine gives us is a sharpening tool in our armory to help protect us from this disease as the virus persists,” said Dr. John Wren. , CEO of MHRA.

Greater protection against variables

The Human Medicines Committee added that the approval represented a step forward in developing a vaccine, especially for viruses with high levels of mutation.

“SARS-CoV-2 is constantly evolving in order to evade the immunity provided by vaccines. This new bivalent vaccine represents the next step in developing vaccines to combat the virus, with the ability to lead to a broader immune response than the original vaccine.”

The approval follows clinical trials, in which the vaccine booster with Moderna’s bivalent vaccine was shown to trigger a robust immune response against both the original 2020 strain as well as Omicron BA.1, which appeared in the UK last winter.

This bivalent vaccine plays an important role in protecting people in the UK from Covid-19 as the winter months enter.

Stephen Bansel

CEO, Moderna

It was also found to generate a good immune response against the omicron sub-variants BA.4 and BA.5, the strains currently prevalent in the country.

distance Release results in JuneModerna CEO Stefan Bancel said he hopes the new iteration will become a “leading candidate for fall 2022.”

“This bivalent vaccine plays an important role in protecting people in the UK from Covid-19 as the winter months enter,” Bancel added in a statement on Monday.

The UK government has not yet announced exactly who will receive the vaccine, but some kind of booster will be offered from next month to all people over 50 and people in the UK at risk groups.

The government lowered the age threshold for those eligible Autumn booster in JulyAfter the virus continues to spread.

Vaccines are one of the most effective ways to reduce the spread and severity of the virus. Research in the medical journal The Lancet in June estimated that Covid-19 vaccines Prevent nearly 20 million deaths In the first year of use.

See also  Lviv, the city in western Ukraine so far spared from the Russian attack, was rocked by powerful explosions